Charles River and BioAtla Partner for Integrated Biological Service for Preclinical Development

Share Article

Charles River and BioAtla have recently partnered to create an integrated biological service for antibodies and other protein therapeutics designed to accelerate drug development for customers from the earliest stages of discovery all the way through IND.

BioAtla logo

Past News Releases

RSS

Charles River and BioAtla have recently partnered to create an integrated biological service for antibodies and other protein therapeutics designed to accelerate drug development for customers from the earliest stages of discovery all the way through IND.

This new partnership combines world-class toxicology services with proprietary, state-of-the-art biological engineering capabilities and represents a significant milestone toward establishing one of the first fully integrated biological services partnership for antibodies and other protein therapeutics. In addition, the international reach of these preferred contract research organizations brings much needed cost-effective integrated services for pharmaceutical development.

About Charles River
Charles River, headquartered in Wilmington, MA, provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Its approximately 8,000 employees worldwide are focused on providing clients with exactly what they need to improve and expedite the discovery, development through first-in-human evaluation, and safe manufacture of new therapies for the patients who need them. For more information, visit http://www.criver.com.

About BioAtla
BioAtla, LLC, is a global biology outsourcing services provider based in San Diego, CA, with research operations in San Diego, New York and Beijing. BioAtla provides an extensive range of protein therapeutic services that include target discovery, humanization, fully human antibody generation, affinity maturation, conditional biologic generation, expression optimization, enzyme engineering, pathway engineering, epitope mapping and more. They are a pioneer in BioAcceleration™, using a global infrastructure to deliver cost-efficient access to state-of-the-art technologies and services and maximizing antibody and other protein product development opportunities for their client partners. For more information, visit http://www.bioatla.com.

Contact:
Carolyn Anderson
Executive Vice President
BioAtla, LLC
858-558-0708 ext. 0
info(at)bioatla(dot)com

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Carolyn Anderson
BioAtla
858-558-0708
Email >
Visit website